On Thursday, Shares of Southwest Airlines Co (NYSE:LUV), lost -0.34% to $ 32.51.
Southwest Airlines Co, declared that it has reached a tentative agreement with its Flight Attendants. Terms of the deal were not released, but the airline said they comprise wage enhances, bonus opportunities, and work-rule adjustments.
“I applaud the efforts of everyone who worked so hard to craft a contract that rewards our Flight Attendants for their excellence,” said Mike Van de Ven, Southwest Airlines Executive Vice President and Chief Operating Officer. “This tentative agreement not only provides additional money, it also supports Southwest’s low-cost structure and positions the Company to be competitive in the years to come.”
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.
Shares of Medtronic PLC (NYSE:MDT), declined -0.35% to $73.82, during its last trading session.
Medtronic plc`s, Solitaire stent retriever device - in conjunction with the current standard of care, IV-t PA, as a first-line treatment for eligible patients.
The guidelines are based on a panel of experts` analysis of the results from five global clinical trials published in The New England Journal of Medicine (NEJM) that found the addition of stent retriever technology, a surgical procedure that manually removes blood clots from the brain, to current medical therapy such as IV-t PA, has a therapeutic benefit over medical therapy alone. These trials showed that the addition of stent retriever technology reduced disability, improved neurological outcomes and raised the rate of return to functional independence in patients suffering stroke.
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
Finally, Array Biopharma Inc (NASDAQ:ARRY), ended its last trade with -1.85% loss, and close at $6.89.
Array BioPharma’s, wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were showcased at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and encorafenib from a Phase 1b/2 dose escalation and expansion study in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive were shared during an oral presentation. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity compriseent with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range presently being used in the Phase 3 COLUMBUS trial. Array anticipates updated BRAF melanoma data from the ongoing Phase 2 combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be presented to a scientific conference later this year. LOGIC-2 utilizes the same dose of binimetinib and encorafenib presently being studied in the COLUMBUS trial.
In the study, patients were treated with binimetinib 45 mg twice daily (BID) and increasing doses of encorafenib once daily (QD) (over the range of 50 to 800 mg and counting doses of 400 and 450 mg, which are comparable to the 450 mg dose being used in the Phase 3 COLUMBUS trial), followed by an expansion phase at the maximum tolerated dose of 600 mg QD. The objective response rate (confirmed complete response or partial response) stated in the trial was 75 percent (41 of 55) for BRAF-naive patients, counting 78 percent (7 of 9) of patients treated with the encorafenib 400/450 mg dose. The estimated median overall progression-free survival for BRAF-naive patients was 11.3 months. These results are compriseent with MEK/RAF inhibitor expectations in BRAF-mutant melanoma patients.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
